The oral cyclophilin inhibitor DEBIO 025 has a "significant antiviral effect" against different genotypes of the hepatitis C virus

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1637, 2008-01, pp. : 8-8

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A Novel Promising Therapeutic Option Against Hepatitis C Virus: An Oral Nucleotide NS5B Polymerase Inhibitor Sofosbuvir

By  

Current Medicinal Chemistry, Vol. 20, Iss. 30, 2013-10 ,pp. : 3733-3742

Bentham Science Publishers

Access to resources Recommend Favorite

Pharmacokinetics of new oral hepatitis C antiviral drugs

By Vispo Eugenia   Barreiro Pablo   Soriano Vicente  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 9, Iss. 1, 2013-01 ,pp. : 5-16

Informa Healthcare

Access to resources Recommend Favorite

Effects of short RNA structural analogues against hepatitis C virus genotypes 2, 3 and 4 in replicon cells

By  

Journal of Digestive Diseases, Vol. 16, Iss. 8, 2015-08 ,pp. : 449-455

John Wiley & Sons Inc

Access to resources Recommend Favorite

Resistance of hepatitis C virus to the host antiviral response

By Polyak Stephen  

Future Virology, Vol. 1, Iss. 1, 2006-01 ,pp. : 89-98

Future Medicine

Access to resources Recommend Favorite

Hepatitis C virus: quasispecies dynamics, virus persistance and antiviral therapy

By Cristina Juan  

Expert Opinion on Therapeutic Patents, Vol. 17, Iss. 5, 2007-05 ,pp. : 499-510

Informa Healthcare

Access to resources Recommend Favorite